uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.
How this was made
The 30-second read
Why it matters
The FDA Type B meeting minutes and planned Q3 2026 BLA submission are the central near-term catalyst, while the upsized $259M follow-on offering reduces financing risk and extends runway into 2030.
Market read
Traders can position around the confirmed regulatory timeline for AMT-130 and the capital raise that funds the pipeline through 2030.
What to watch
The article highlights cash runway and funding, but does not quantify commercial launch assumptions or potential dilution impact beyond the gross proceeds, which can affect valuation sensitivity.
Background
uniQure is advancing multiple gene therapy programs, with AMT-130 as the lead Huntington’s disease asset and AMT-260/AMT-191 in earlier-stage development.
Ticker impact
uniQure reports Q2 2026 results and says FDA Type B minutes confirm a Q3 2026 BLA submission plan for AMT-130 under accelerated approval.
Likely supportive near-term bias into the earnings call and toward Q3 BLA submission expectations, with volatility tied to confirmatory study design details.
The article discloses primary, time-specific items: FDA meeting minutes alignment, planned BLA submission in Q3 2026, and a completed upsized follow-on offering that funds the program through 2030.
Market effects
Reinforces investor read-through that FDA accelerated-approval pathways for gene therapies can be navigated with confirmatory study design alignment.
Limited direct regional impact beyond sentiment for US-listed gene therapy peers.
Supports broader confidence in cross-regulatory execution (FDA and MHRA) for Huntington’s disease programs.
Counterpoint
Early biological signals and FDA alignment do not remove the key execution risk that confirmatory study design and enrollment timelines could slip.
Key entities
- companyuniQure N.V.
NASDAQ-listed gene therapy company reporting Q2 2026 financial results and program updates.
- product_candidateAMT-130
Huntington’s disease gene therapy program; company expects Q3 2026 BLA submission under accelerated approval pathway.
- product_candidateAMT-260
Refractory mesial temporal lobe epilepsy program; early cohort data show biological signals and favorable safety profile.
- product_candidateAMT-191
Fabry disease program; dosing paused in mid/high cohorts pending evaluation of asymptomatic liver enzyme elevations.
- regulatorFDA
US regulator; Type B meeting minutes confirm BLA submission reasonableness and discuss confirmatory study design.
